Skip to main content
Top
Published in: Tumor Biology 9/2014

01-09-2014 | Research Article

Association of p73 G4C14-to-A4T14 polymorphism with lung cancer risk

Authors: Hua Liu, Yuli Liang, Hua Liao, Lanying Li, Hongyun Wang

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

Conflicting results were implicated in both single case-control studies and meta-analyses of the correlation between p73 G4C14-to-A4T14 polymorphism and lung cancer risk. We designed this study to further assess the association by meta-analysis. A meta-analysis was performed based on five case-control studies (5,467 subjects) retrieved from PubMed and Embase. Odds ratios (ORs) with 95 % confidence intervals (CIs) were measured for the association using the models of random effects and fixed effects. The results showed no evidence between p73 G4C14-to-A4T14 polymorphism and lung cancer risk in any genetic model (allele model: OR, 1.06, 95 % CI, 0.89–1.26; homozygote genotypes: OR, 1.18, 95 % CI, 0.80–1.73; heterozygote genotypes: OR, 1.04, 95 % CI, 0.89–1.23; dominant model: OR, 1.05, 95 % CI, 0.89–1.24; recessive model: OR, 1.17, 95 % CI, 0.93–1.47). Subgroup analyses according to ethnicity, however, detected significant association in Caucasian population. Our study provides evidence that p73 G4C14-to-A4T14 polymorphism may play a major role in susceptibility to lung cancer in Caucasians.
Literature
1.
go back to reference Hsu NY et al. Lung cancer susceptibility and genetic polymorphism of DNA repair gene XRCC4 in Taiwan. Cancer Biomark. 2009;5(4):159–65.PubMed Hsu NY et al. Lung cancer susceptibility and genetic polymorphism of DNA repair gene XRCC4 in Taiwan. Cancer Biomark. 2009;5(4):159–65.PubMed
2.
go back to reference Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4(1):87–92.PubMed Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4(1):87–92.PubMed
3.
go back to reference Pavanello S et al. Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study. Cancer Genet. 2012;205(6):278–84.CrossRefPubMed Pavanello S et al. Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study. Cancer Genet. 2012;205(6):278–84.CrossRefPubMed
4.
go back to reference Zhang Y et al. Association between polymorphisms in COMT, PLCH1, and CYP17A1, and non-small-cell lung cancer risk in Chinese nonsmokers. Clin Lung Cancer. 2013;14(1):45–9.CrossRefPubMed Zhang Y et al. Association between polymorphisms in COMT, PLCH1, and CYP17A1, and non-small-cell lung cancer risk in Chinese nonsmokers. Clin Lung Cancer. 2013;14(1):45–9.CrossRefPubMed
5.
go back to reference Robles AI, Harris CC. p53-mediated apoptosis and genomic instability diseases. Acta Oncol. 2001;40(6):696–701.CrossRefPubMed Robles AI, Harris CC. p53-mediated apoptosis and genomic instability diseases. Acta Oncol. 2001;40(6):696–701.CrossRefPubMed
6.
go back to reference Melino G et al. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci. 2003;28(12):663–70.CrossRefPubMed Melino G et al. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci. 2003;28(12):663–70.CrossRefPubMed
7.
go back to reference Wang XQ et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001;61(4):1598–603.PubMed Wang XQ et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001;61(4):1598–603.PubMed
8.
go back to reference Kaghad M et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90(4):809–19.CrossRefPubMed Kaghad M et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90(4):809–19.CrossRefPubMed
9.
go back to reference Davis, P.K., and Dowdy, S. F., p73. Int. J. Biochem. Cell Biol., 2001. 33: p. 935. Davis, P.K., and Dowdy, S. F., p73. Int. J. Biochem. Cell Biol., 2001. 33: p. 935.
10.
go back to reference Nomoto S et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58(7):1380–3.PubMed Nomoto S et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58(7):1380–3.PubMed
11.
go back to reference Ikawa S, Nakagawara A, Ikawa Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 1999;6(12):1154–61.CrossRefPubMed Ikawa S, Nakagawara A, Ikawa Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 1999;6(12):1154–61.CrossRefPubMed
12.
go back to reference Ibrahim N et al. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 2010;70(18):7155–65.PubMedCentralCrossRefPubMed Ibrahim N et al. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 2010;70(18):7155–65.PubMedCentralCrossRefPubMed
13.
go back to reference Moll UM, Erster S, Zaika A. p53, p63 and p73–solos, alliances and feuds among family members. Biochim Biophys Acta. 2001;1552(2):47–59.PubMed Moll UM, Erster S, Zaika A. p53, p63 and p73–solos, alliances and feuds among family members. Biochim Biophys Acta. 2001;1552(2):47–59.PubMed
14.
go back to reference Marabese M, Vikhanskaya F, Broggini M. p73: a chiaroscuro gene in cancer. Eur J Cancer. 2007;43(9):1361–72.CrossRefPubMed Marabese M, Vikhanskaya F, Broggini M. p73: a chiaroscuro gene in cancer. Eur J Cancer. 2007;43(9):1361–72.CrossRefPubMed
15.
go back to reference Daskalos A et al. Global DNA hypomethylation-induced DeltaNp73 transcriptional activation in non-small cell lung cancer. Cancer Lett. 2011;300(1):79–86.CrossRefPubMed Daskalos A et al. Global DNA hypomethylation-induced DeltaNp73 transcriptional activation in non-small cell lung cancer. Cancer Lett. 2011;300(1):79–86.CrossRefPubMed
16.
17.
go back to reference Peters MA et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48(4):292–6.CrossRefPubMed Peters MA et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48(4):292–6.CrossRefPubMed
18.
go back to reference Li G et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004;64(19):6863–6.CrossRefPubMed Li G et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004;64(19):6863–6.CrossRefPubMed
19.
go back to reference Zhang X et al. The p73 G4C14-to-A4T14 polymorphism is associated with risk of lung cancer in the Han nationality of North China. Mol Carcinog. 2013;52(5):387–91.CrossRefPubMed Zhang X et al. The p73 G4C14-to-A4T14 polymorphism is associated with risk of lung cancer in the Han nationality of North China. Mol Carcinog. 2013;52(5):387–91.CrossRefPubMed
20.
go back to reference Hiraki A et al. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 2003;4(2):107–12.PubMed Hiraki A et al. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 2003;4(2):107–12.PubMed
21.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
22.
24.
go back to reference Choi JE et al. No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet. 2006;44(11–12):543–50.PubMed Choi JE et al. No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet. 2006;44(11–12):543–50.PubMed
25.
go back to reference Schabath MB et al. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(1):158–61.CrossRefPubMed Schabath MB et al. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(1):158–61.CrossRefPubMed
26.
go back to reference Yuan P et al. Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]. Zhonghua Zhong Liu Za Zhi. 2006;28(2):107–10.PubMed Yuan P et al. Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]. Zhonghua Zhong Liu Za Zhi. 2006;28(2):107–10.PubMed
27.
go back to reference Liu L et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6(11):1793–800.CrossRefPubMed Liu L et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6(11):1793–800.CrossRefPubMed
28.
go back to reference Hu Z et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114(3):455–60.CrossRefPubMed Hu Z et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114(3):455–60.CrossRefPubMed
29.
go back to reference Jun HJ et al. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog. 2007;46(2):100–5.CrossRefPubMed Jun HJ et al. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog. 2007;46(2):100–5.CrossRefPubMed
30.
go back to reference Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008;18(5):244–52.CrossRefPubMed Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008;18(5):244–52.CrossRefPubMed
31.
go back to reference Wang L et al. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Mol Biol Rep. 2011;38(1):229–36.CrossRefPubMed Wang L et al. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Mol Biol Rep. 2011;38(1):229–36.CrossRefPubMed
32.
go back to reference Hu Y et al. Association between the p73 exon 2 G4C14-to-A4T14 polymorphism and cancer risk: a meta-analysis. DNA Cell Biol. 2012;31(2):230–7.CrossRefPubMed Hu Y et al. Association between the p73 exon 2 G4C14-to-A4T14 polymorphism and cancer risk: a meta-analysis. DNA Cell Biol. 2012;31(2):230–7.CrossRefPubMed
Metadata
Title
Association of p73 G4C14-to-A4T14 polymorphism with lung cancer risk
Authors
Hua Liu
Yuli Liang
Hua Liao
Lanying Li
Hongyun Wang
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2061-3

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine